chlorpheniramine has been researched along with Disorders of Excessive Somnolence in 2 studies
Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.
chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.
Disorders of Excessive Somnolence: Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Loratadine was significantly superior to placebo in 3 of 10 trials (30%), consistent with rates found in 3 pivotal group trials used for FDA approval (24%, 17%, and 0%)." | 2.70 | Single-patient drug trial methodology for allergic rhinitis. ( Del Rio, E; Rebell, G; Reitberg, DP; Weiss, SL; Zaias, N, 2002) |
| "Excessive daytime sleepiness, which had occurred in the cases as an H1-antihistamine-induced ADR, was assessed by the Epworth sleepiness scale (ESS), and an ESS score >or=12 was considered hypersomnia." | 1.33 | Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia. ( Ikeda, K; Kamataki, T; Marubayashi, T; Matsunaga, M; Mihara, S; Nakagawa, K; Nakao, M; Oniki, K; Saruwatari, J; Seo, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reitberg, DP | 1 |
| Del Rio, E | 1 |
| Weiss, SL | 1 |
| Rebell, G | 1 |
| Zaias, N | 1 |
| Saruwatari, J | 1 |
| Matsunaga, M | 1 |
| Ikeda, K | 1 |
| Nakao, M | 1 |
| Oniki, K | 1 |
| Seo, T | 1 |
| Mihara, S | 1 |
| Marubayashi, T | 1 |
| Kamataki, T | 1 |
| Nakagawa, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prescription Methods Assessment Project (PMAP)[NCT00393653] | 800 participants (Anticipated) | Interventional | 2006-10-31 | Terminated (stopped due to Funding ended early) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for chlorpheniramine and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Single-patient drug trial methodology for allergic rhinitis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Chlorpheniramine; Clinical Trials as Topic; Da | 2002 |
1 other study available for chlorpheniramine and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia.
Topics: Asian People; Chlorpheniramine; Clemastine; Cytochrome P-450 CYP2D6; Disorders of Excessive Somnolen | 2006 |